Quantum-Si Incorporated reported its financial results for the second quarter of 2025, revealing a total revenue of $591,000, a decrease of 5% compared to $622,000 in the same period of 2024. For the first half of 2025, revenue increased by 32.8% to $1.43 million, up from $1.08 million in the prior year. The company attributed the quarterly decline to longer capital sales cycles and budget constraints from customers, particularly related to funding from the National Institutes of Health (NIH). Despite the quarterly dip, product revenue for the six months ended June 30, 2025, rose significantly, driven by increased sales of its Platinum line of instruments.
The company's net loss for the second quarter was $28.8 million, compared to a loss of $23.1 million in the same quarter of 2024, marking a 24.8% increase in losses year-over-year. For the first half of 2025, the net loss was $48 million, up from $42.6 million in the previous year. The increase in losses was primarily due to higher operating expenses, which rose by 13.7% in the second quarter and 11.2% in the first half, largely driven by legal settlement expenses related to a class action lawsuit.
In terms of operational developments, Quantum-Si's employee headcount remained stable, and the company continued to focus on its research and development efforts, which saw an increase in spending. Research and development expenses for the second quarter were $15.2 million, up 5.8% from the previous year, reflecting ongoing investments in product development, including the anticipated launch of its next-generation platform, Proteus, in 2026. The company also reported a legal settlement liability of $8 million related to the Delaware Stockholder Litigation, which was recorded in the second quarter.
Quantum-Si's cash and cash equivalents, along with marketable securities, totaled $214.2 million as of June 30, 2025, providing a solid liquidity position to support ongoing operations and commercialization efforts. The company expects its current cash reserves, combined with revenue from product sales, to be sufficient to fund operations for at least the next twelve months. Looking ahead, Quantum-Si plans to continue its phased approach to product launches and enhancements, while also exploring additional financing options to support its growth strategy.
About Quantum-Si Inc
Quantum-Si Incorporated develops proteomics research tools, including innovative single-molecule protein sequencing instruments, consumables, and software. Its platforms enable detailed analysis of proteins, variants, and post-translational modifications, serving life sciences research, drug discovery, and diagnostics markets. Focused on broad accessibility, the company offers low-cost, automated solutions to enhance proteomics capabilities across diverse laboratories worldwide. Its technology aims to revolutionize protein analysis with high resolution, automation, and scalability.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.